Torrent Pharma launches Adalimumab biosimilar in India
Advertisement
New Delhi: Drug firm Torrent Pharmaceuticals has launched in India its biosimilar Adalimumab, used for the treatment of auto immune disorders, under the brand name 'Adfrar'.
The company's product will be available as pre-filled syringe of 40 mg, Torrent Pharmaceuticals said in a statement.
It, however, did not give any details about the price at which the biosimilar will be available.
Adalimumab is a preferred therapy for the treatment of auto immune disorders and has wide applications for treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis and plaque psoriasis among others, Torrent Pharmaceuticals said.
Autoimmune disorders are growing ailments and monoclonal antibodies (MAb's) are becoming mainstay of treatment, it added.
Biosimilars are biological products that are similar or highly similar to the originator products and have similar level of efficacy and safety.
The company's product will be available as pre-filled syringe of 40 mg, Torrent Pharmaceuticals said in a statement.
It, however, did not give any details about the price at which the biosimilar will be available.
Adalimumab is a preferred therapy for the treatment of auto immune disorders and has wide applications for treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis and plaque psoriasis among others, Torrent Pharmaceuticals said.
Autoimmune disorders are growing ailments and monoclonal antibodies (MAb's) are becoming mainstay of treatment, it added.
Biosimilars are biological products that are similar or highly similar to the originator products and have similar level of efficacy and safety.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.